South Korea Gene Therapy Market Assessment, By Type [Gene Augmentation, Gene Silencing, Others], By Vector [Viral Vectors, Non-Viral Vectors], By Gene Delivery Method [In vivo, Ex vivo], By Application [Oncological Diseases, Genetic Diseases, Cardiovascul

South Korea Gene Therapy Market Assessment, By Type [Gene Augmentation, Gene Silencing, Others], By Vector [Viral Vectors, Non-Viral Vectors], By Gene Delivery Method [In vivo, Ex vivo], By Application [Oncological Diseases, Genetic Diseases, Cardiovascular Diseases, Neuromuscular Diseases, Hematological Diseases, Infectious Diseases, Others], By Route of Administration [Intravenous, Others], By End-user [Hospitals, Cancer and Research Institutes, Clinics, Others], By Region, Opportunities and Forecast, 2017-2031F

Global non-opioids pain treatment market is projected to witness a CAGR of 7.86% during the forecast period 2024-2031, growing from USD 50.05 billion in 2023 to USD 91.68 billion in 2031. The market demands for non-opioid pain treatment pharmaceutical products is anticipated to thrive in the forecast period due to increased awareness of opioid crisis and risks associated with the use of opioids, including addiction and overdose, pushing both patients and medical workers to look for alternative options like non-opioids for treating pain.

An increase in the prevalence of chronic pain conditions such as cancer pain, arthritis pain, and lower back pain, heart disease has led to increases in an increased demand for non-opioid analgesics in the market. Ongoing research into new therapies, such as nonsteroidal anti-inflammatory drugs (NSAIDs), non-opioid pain relief methods such as acetaminophen, and cannabinoids, has significantly expanded the treatment options. Regulatory changes, governments, and healthcare organizations are implementing stricter regulations regarding the prescription of opioids and encouraging the development and use of non-opioid pain relief treatments. The development of new delivery systems, such as transdermal patches, injections, and implantable devices, increases the effectiveness of non-opioid treatments. Semnur Pharmaceuticals, a company developing a non-opioid treatment for sciatica, has agreed to merge with Denali Capital Acquisition Corp. The transaction is valued at USD 2.5 billion and is expected to close by the first quarter of 2025. Following the completion of the merger, Semnur aims to continue the path toward the potential commercialization of its leading drug candidate, Semdexa, which is an injectable corticosteroid gel formulation of dexamethasone sodium phosphate, designed to treat moderate to severe lumbosacral radicular pain, commonly known as sciatica.

Increasing Awareness of Risks Related to the Use of Opioids

Increasing awareness of risks related to the use of opioids has become an important issue in healthcare and has considerably improved the practice of pain. It is estimated that over 6.1 million people aged 12 or older have an opioid use disorder (OUD). This consciousness, which was pampered by the trend of opioids and led to unprecedented dependence levels, overdose, and death, emphasized the seriousness of the situation, causing a wide range of lighting and public health campaigns in the media. Personal stories and alarming statistics effectively illustrate the potential dangers of opioid medications and have contributed to a climate of concern. In response, healthcare organizations and patient advocacy groups have prioritized educational efforts aimed at both healthcare providers and patients. These initiatives highlight the risks of addiction and the importance of exploring non-opioid alternatives for pain relief. Regulatory bodies are implementing stricter guidelines on opioid prescriptions and are encouraging doctors to assess risks and consider safer treatment options. Increased awareness of risks related to the use of opioids will automatically reflect into increased demand for non-opioid drugs. In May 2023, the U.S. Food and Drug Administration approved Brixadi (buprenorphine), an extended-release injection for subcutaneous route to treat moderate to severe opioid use disorder (OUD). Brixadi is available in two formulations, a weekly injection that can be used in patients who have started treatment with a single dose of a transmucosal buprenorphine product. or who are already being treated with buprenorphine, and a monthly version for patients already being treated with buprenorphine.

Advancement in Pain Management Research

Recent advancements in pain treatment research are changing the way to manage chronic pain, driven by the need to find safer alternatives to opioids. Key developments include the advent of biologics and targeted therapies that focus on specific pain pathways, as well as neuromodulation techniques such as spinal cord stimulation, which modify nerve activity to provide relief. The growth of the non-opioid market is driven by the increasing prevalence of chronic pain which is affecting millions of individuals globally with conditions such as arthritis and lower back pain. Additionally, the aging population prevalence of the condition and lifestyle factors, poor diet, and obesity have been linked to a rise in conditions such as back pain, joint issues, and neuropathic pain. Neuropathic pain, which affects the nervous system, is exacerbated by conditions such as diabetic neuropathy and chemotherapy-induced peripheral neuropathy, so there is a huge demand for effective treatments. The industry's focus on developing suitable treatments for various types of chronic pain patients is supported by governing bodies. This will enable researchers and pharmaceutical companies to advance the treatment of chronic pain management. The rising awareness about chronic pain is driving the growth of the non-opioid analgesics market. For instance, in January 2024, researchers at the University of Texas at Austin identified a potential non-opioid treatment. A new approach to treating neuropathic pain is taking a key step forward. Neuropathic pain is among the most difficult types of pain to alleviate, and current treatments are often ineffective.

NSAIDs Segment to Dominate the Non-Opioid Pain Treatment Market

The NSAIDs segment is likely to dominate the non-opioid pain treatment as they most effectively alleviate pain and inflammation resulting from a variety of conditions. NSAIDs are commonly prescribed medications to treat mild to moderate-level pain and, therefore, they are the first-line prescribing option, due to their established efficacy and a favorable safety profile when given at recommended dosages. With several formulations available-from over the counter like ibuprofen or naproxen to prescription strength medications-NSAIDs represent versatility in pain management. The increasing use of NSAIDs is also promoted by growing awareness about the risks associated with opioid use as well as the campaigns and efforts for safer, nonaddictive alternatives for pain relief. This segment would likely expand further with more patients on the lookout for effective solutions with fewer side effects and overall dominance in the market for non-opioid pain treatment. For instance, in August 2023, Zydus Lifesciences was granted final approval from the Food and Drug Administration to manufacture and market generic indomethacin 50 mg suppositories. Indomethacin, a non-steroidal, anti-inflammatory therapy, is indicated for moderate to severe rheumatoid arthritis, including acute flares of chronic disease.

North America Dominates the Non-Opioid Pain Treatment Market

North America dominates the non-opioid pain treatment markets due to the prevalence of chronic pain, neuropathic pain, and postoperative surgical pain. Chronic pain is a condition that affects the daily life of many adults in the United States. Around 1 in 20 U.S. adults with chronic pain have clinically significant symptoms of anxiety and depression. Approximately 12 million Americans, 55.6% percentage of U.S. adults, report chronic pain and also have persistent anxiety or depression compared with 17.1% of adults with chronic pain who do not report symptoms of anxiety or depression. A 69.4% percentage of U.S. adults with coexisting chronic pain, depression, and anxiety disorders report that their health condition limits their ability to work. Meanwhile, 43.7% of this population reported difficulty running errands alone, and 55.7% said they had difficulty participating in social activities. In Oct 2023, Hyloris Pharmaceuticals, a Belgium-based pharmaceutical company, announced the U.S. Food and Drug Administration approved the New Drug Application for Maxigesic IV as a treatment for mild-to-moderate pain and adjunct therapy for moderate to severe pain. Partnering with AFT Pharmaceuticals, Hyloris developed Maxigesic IV as an alternative to opioid painkillers after surgical procedures.

Future Market Scenario (2024-2031F)

The non-opioid pain treatment market is poised to witness significant growth driven by ongoing concerns over opioid addiction and an increasing focus on comprehensive pain management solutions. Advancements in research and technology are likely to lead to the development of innovative non-opioid treatments, including targeted biologics, neuromodulation devices, and regenerative medicine techniques. Furthermore, the increasing prevalence of chronic pain, especially among the elderly, will continue to fuel the demand for effective pain management options. Regulatory support for non-opioid alternatives, along with increased awareness among healthcare providers and patients about the risks associated with opioid use, will further bolster the market dynamics. The integration of digital health solutions and telemedicine is expected to drive patient engagement and personalized care, improving access to non-opioid treatments. As these trends converge, the non-opioid pain treatment market is expected to expand significantly and become a key component of the future pain treatment landscape. Companies that will focus on developing advanced new formulations and alternative pain management solutions are likely to see growth in this market. Collaboration with regulators and healthcare providers is key to shaping a responsible future for the non-opioid pain treatment market.

Key Players Landscape and Outlook

The non-opioid pain management market is highly dynamic, with several leading players like Pfizer Inc., Johnson & Johnson Services, Inc., Teva Pharmaceuticals Industries Ltd., Novartis AG., Sun Pharmaceuticals Industries Ltd., Fresenius Kabi AG., Dr.Reddy's Laboratories Ltd ., Cipla Inc., Amgen Inc., Sanofi S.A. Corporation. Significant market activities have been reported in recent times including distribution agreements and acquisitions alongside several product launches. The market players are taking several initiatives and are actively involved in developmental moves to bring growth to this market.

On 30 Jan 2024, Vertex Pharmaceuticals' (VRTX.O), launched an experimental drug to decrease acute, post-surgical pain without the risk of addiction, a big milestone in the company's decades-long efforts to bring a non-opioid pain medicine to market. The company plans to file for U.S. approval by mid-2024 for the drug. The drug works by blocking pain signals at their origin before they reach the brain. If the drug gets approved, it could achieve an annual sale of more than USD 5 billion.